Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus...
Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
About this item
Full title
Author / Creator
Korfei, Martina , Stelmaszek, Daniel , MacKenzie, BreAnne , Skwarna, Sylwia , Chillappagari, Shashipavan , Bach, Anna C , Ruppert, Clemens , Saito, Shigeki , Mahavadi, Poornima , Klepetko, Walter , Fink, Ludger , Seeger, Werner , Lasky, Joseph A , Pullamsetti, Soni S , Krämer, Oliver H and Guenther, Andreas
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a poor prognosis. Pirfenidone is the first antifibrotic agent to be approved for IPF-treatment as it is able to slow down disease progression. However, there is no curative treatment other than lung transplantation. Because epigenetic alterations are associated with IPF, histone...
Alternative Titles
Full title
Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_2138604138
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2138604138
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0207915
